Introducing RCC19: The EAU’s first meeting dedicated to renal cancers

01 March 2019

Axel Bex Introducing RCC19

The Czech capital is set to host the EAU’s first Update on Renal Cell Cancer. RCC19 is the second of the “Update” meetings that the EAU is holding this year, following BCA19 and ahead of PCA19. The goal of this meeting is to offer the practicing urologist a comprehensive overview of the latest developments in renal cell cancer.

We spoke to Prof. Axel Bex (London, GB), co-chairman of the RCC19 Scientific Committee and one of the speakers in Prague on 7-8 June.

Prof. Bex is Consultant Clinical Lead at the Specialist Centre for Kidney Cancer at the Royal Free London NHS Foundation Trust. Bex is also affiliated with the UCL Division of Surgery and Interventional Science (London) and the Netherlands Cancer Institute (Amsterdam).

In Prague, Prof. Bex will co-chair the immunotherapy update on locally advanced and metastatic RCC, speak on case discussions on choosing and prescribing first-line systemic agents in metastatic RCC, and he is one of the panelists on the interdisciplinary management of metastatic RCC.

Starting a new meeting

“Kidney cancer management is going through a period of great and rapid changes,” Prof. Bex explains. “There are some exciting new developments, especially in the field of systemic therapy which not only led to new treatment paradigms but several adjuvant and neoadjuvant trials in which urologists are involved.”

Some of the hotter RCC-related topics that will be addressed in Prague are, according to Prof. Bex: “Small renal masses are increasingly being diagnosed, so we will be talking about their management. Particular attention will be given to the introduction of immunotherapy and combination therapies into RCC management.”

The EAU feels it is important for urologists to familiarise themselves with the latest generation of immuno-oncologic agents to be able to make informed decisions in a multidisciplinary setting. Urologists might not be actively involved with the delivery of the drugs, but they can learn to identify suitable patients and they should also be aware of the drugs’ impact on their patients’ quality of life.

Target audience

As one of the onco-urology update meetings, RCC19 has a programme that is slanted towards evidence-based education, rather than cutting-edge new developments. Still, as the first edition of the meeting, much of the scientific programme is brand new and based on this rapidly-developing field.

Bex: “RCC19 will be an educational meeting, but with a strong focus on new developments in the management of localised, locally-advanced and metastatic RCC.”

“In a nutshell, we want this meeting to be of interest for a multidisciplinary audience. We want to attract urologists, oncologists, radiologists and radiation oncologists who have a special interest in kidney cancer. We are offering a condensed update within the framework of a single meeting.”

  • Early registration, including accommodation is open until March 6th, so register today!